Perceptive Advisors LLC has demonstrated a clear buying bias in recent months, with $142.3 million in total purchases across three companies compared to $18.7 million in sales, according to SEC Form 4 filings. The firm's most significant recent acquisition was a $49.99 million stake in Solid Biosciences (SLDB) on March 9, 2026, marking one of its largest single transactions. Prior to this, Perceptive made a concentrated series of purchases in Athira Pharma (ATHA) on December 23, 2025, totaling approximately $75.4 million across nine separate transactions ranging from $2.09 million to $24.4 million. These buys were partially offset by the disposition of its entire $18.2 million position in MeiraGTx Holdings (MGTX) on December 31, 2025.
The firm has also been unwinding smaller positions in Lyra Therapeutics (LYRA) through a steady stream of sales between November 6 and November 13, 2025, totaling just $526,000. Earlier activity included acquiring shares of Adamis Pharmaceuticals (ADGM) in October 2025 for $3.75 million. While Perceptive's recent trades show a net accumulation pattern, the two most recent months reveal a shift toward selective selling, with 12 disposals versus just two purchases. The firm continues to maintain concentrated positions in biotech names, particularly ATHA and SLDB, which account for the bulk of its recent investment activity.
AI-assisted summary